Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000385949

Medchemexpress LLC Dofequidar fumarate | 153653-30-6 | 98.0% | 597.66 | 50 MG
SDP

Catalog No. 5000385949
Encompass_Preferred

Dofequidar fumarate (MS-209) is an orally active quinoline compound that blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). It has a highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp and ABCC1/MRP-1, blocking the efflux of chemotherapeutic agents, increasing drug concentration in cancer cells, and enhancing the chemotherapeutic effect. It is for research use only and not sold to patients.

  • Orally active quinoline compound.
  • Blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1).
  • Highly potent reversing effect on multidrug-resistant tumor cells.
  • Competitively inhibits ABCB1/P-gp and ABCC1/MRP-1.
  • Blocks the efflux of chemotherapeutic agents.
  • Increases drug concentration in cancer cells.
  • Enhances the chemotherapeutic effect.

Catalog No. 50-003-85949 Supplier Medchemexpress LLC Supplier No. HY17013A50MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Dofequidar fumarate (MS-209) is an orally active quinoline compound that blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). It has a highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp and ABCC1/MRP-1, blocking the efflux of chemotherapeutic agents, increasing drug concentration in cancer cells, and enhancing the chemotherapeutic effect. It is for research use only and not sold to patients.

  • Orally active quinoline compound.
  • Blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1).
  • Highly potent reversing effect on multidrug-resistant tumor cells.
  • Competitively inhibits ABCB1/P-gp and ABCC1/MRP-1.
  • Blocks the efflux of chemotherapeutic agents.
  • Increases drug concentration in cancer cells.
  • Enhances the chemotherapeutic effect.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.